Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Combination therapy for the treatment of neovascular age-related macular degeneration.

Englander M, Kaiser PK.

Curr Opin Ophthalmol. 2013 May;24(3):233-8. doi: 10.1097/ICU.0b013e32835f8eaa. Review.

PMID:
23429601
2.

Preferred therapies for neovascular age-related macular degeneration.

Lally DR, Gerstenblith AT, Regillo CD.

Curr Opin Ophthalmol. 2012 May;23(3):182-8. doi: 10.1097/ICU.0b013e328352411c. Review.

PMID:
22450218
3.

Does laser still have a role in the management of retinal vascular and neovascular diseases?

Shah AM, Bressler NM, Jampol LM.

Am J Ophthalmol. 2011 Sep;152(3):332-339.e1. doi: 10.1016/j.ajo.2011.04.015. Epub 2011 Jul 13.

PMID:
21742309
4.

Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration.

Broadhead GK, Hong T, Chang AA.

Acta Ophthalmol. 2014 Dec;92(8):713-23. doi: 10.1111/aos.12463. Epub 2014 Jun 12. Review.

5.

Radiation therapy: age-related macular degeneration.

Mendez CA, Ehlers JP.

Dev Ophthalmol. 2013;52:75-84. doi: 10.1159/000351061. Epub 2013 Aug 26. Review.

PMID:
23989128
6.

Review of combination therapies for neovascular age-related macular degeneration.

Couch SM, Bakri SJ.

Semin Ophthalmol. 2011 May;26(3):114-20. doi: 10.3109/08820538.2011.577130. Review.

PMID:
21609223
7.

Anti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: is this the new deal?

Neri P, Mariotti C, Arapi I, Bambini E, Giovannini A.

Curr Med Res Opin. 2012 Mar;28(3):395-400. doi: 10.1185/03007995.2012.662153. Epub 2012 Feb 14. Review.

PMID:
22283373
8.

Anti-VEGF compounds in the treatment of neovascular age related macular degeneration.

Campa C, Harding SP.

Curr Drug Targets. 2011 Feb;12(2):173-81. Review.

PMID:
20887245
9.

Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review.

Lanzetta P, Mitchell P, Wolf S, Veritti D.

Br J Ophthalmol. 2013 Dec;97(12):1497-507. doi: 10.1136/bjophthalmol-2013-303394. Epub 2013 Aug 8. Review.

PMID:
23929309
10.

Anti-vascular endothelial growth factor therapy for ocular neovascular disease.

Andreoli CM, Miller JW.

Curr Opin Ophthalmol. 2007 Nov;18(6):502-8. Review.

PMID:
18163003
11.

Neovascular age-related macular degeneration: potential therapies.

Chappelow AV, Kaiser PK.

Drugs. 2008;68(8):1029-36. Review.

PMID:
18484796
12.

Guidance for the treatment of neovascular age-related macular degeneration.

Schmidt-Erfurth UM, Richard G, Augustin A, Aylward WG, Bandello F, Corcòstegui B, Cunha-Vaz J, Gaudric A, Leys A, Schlingemann RO; European Society for Retina Specialists' Guidelines Committee (EURETINA).

Acta Ophthalmol Scand. 2007 Aug;85(5):486-94. Review.

13.

Current and future therapies for age-related macular degeneration.

Beutel J, Rudolf M, Grisanti S.

Expert Opin Emerg Drugs. 2009 Jun;14(2):341-62. doi: 10.1517/14728210902824141 . Review.

PMID:
19392638
14.

Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.

Ciulla TA, Rosenfeld PJ.

Curr Opin Ophthalmol. 2009 May;20(3):166-74. doi: 10.1097/ICU.0b013e328329d173. Review.

PMID:
19381089
15.

Emerging therapies for the treatment of neovascular age related macular degeneration.

Yuan A, Kaiser PK.

Semin Ophthalmol. 2011 May;26(3):149-55. doi: 10.3109/08820538.2011.570846. Review.

PMID:
21609228
16.

[Contributions to the treatment of atypical forms of age-related macular degeneration].

Esteban González E, Cervera Taulet E.

Arch Soc Esp Oftalmol. 2012 Dec;87 Suppl 1:18-26. doi: 10.1016/S0365-6691(12)70048-5. Review. Spanish.

PMID:
23380437
17.

Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy.

Arias L, Caminal JM, Badia MB, Rubio MJ, Catala J, Pujol O.

Retina. 2010 Nov-Dec;30(10):1601-8. doi: 10.1097/IAE.0b013e3181e9f942.

PMID:
21060271
18.

Patient characteristics and treatment of neovascular age-related macular degeneration in France: the LUEUR1 observational study.

Cohen SY, Souied EH, Weber M, Dupeyron G, de Pouvourville G, Lievre M, Ponthieux A.

Graefes Arch Clin Exp Ophthalmol. 2011 Apr;249(4):521-7. doi: 10.1007/s00417-010-1553-0. Epub 2010 Nov 6.

PMID:
21057805
19.

Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries.

Curtis LH, Hammill BG, Qualls LG, DiMartino LD, Wang F, Schulman KA, Cousins SW.

Am J Ophthalmol. 2012 Jun;153(6):1116-24.e1. doi: 10.1016/j.ajo.2011.11.032. Epub 2012 Feb 8.

PMID:
22321802
20.

Current and emerging concepts in the management of neovascular age-related macular degeneration.

Maloney SC, Godeiro KD, Odashiro AN, Burnier MN Jr.

Cardiovasc Hematol Agents Med Chem. 2007 Apr;5(2):147-54. Review.

PMID:
17430137

Supplemental Content

Support Center